JP2011521660A - エリスロポイエチンを発酵により製造する方法 - Google Patents
エリスロポイエチンを発酵により製造する方法 Download PDFInfo
- Publication number
- JP2011521660A JP2011521660A JP2011512115A JP2011512115A JP2011521660A JP 2011521660 A JP2011521660 A JP 2011521660A JP 2011512115 A JP2011512115 A JP 2011512115A JP 2011512115 A JP2011512115 A JP 2011512115A JP 2011521660 A JP2011521660 A JP 2011521660A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- fermentation
- erythropoietin
- particularly preferably
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 70
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 69
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 69
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 238000000855 fermentation Methods 0.000 title claims abstract description 44
- 230000004151 fermentation Effects 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 65
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 33
- 239000008103 glucose Substances 0.000 claims abstract description 33
- 230000010412 perfusion Effects 0.000 claims abstract description 30
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 9
- 239000006228 supernatant Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims description 23
- 230000014759 maintenance of location Effects 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000012228 culture supernatant Substances 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 7
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 102000044890 human EPO Human genes 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 238000010924 continuous production Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000006229 amino acid addition Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 238000012262 fermentative production Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000009450 sialylation Effects 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000012737 fresh medium Substances 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000019522 cellular metabolic process Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000004017 serum-free culture medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000013028 medium composition Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 0 C*IONOC(*)[N+](CCIIC*[Os]O*C([*+]=C)III)[O-] Chemical compound C*IONOC(*)[N+](CCIIC*[Os]O*C([*+]=C)III)[O-] 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000006706 cellular oxygen consumption Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 238000009406 nutrient management Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008002210.1 | 2008-06-04 | ||
| DE102008002210A DE102008002210A1 (de) | 2008-06-04 | 2008-06-04 | Verfahren zur fermentativen Herstellung von Erythropoietin |
| PCT/EP2009/056820 WO2009147175A1 (de) | 2008-06-04 | 2009-06-03 | Verfahren zur fermentativen herstellung von erythropoietin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521660A true JP2011521660A (ja) | 2011-07-28 |
| JP2011521660A5 JP2011521660A5 (enExample) | 2012-07-05 |
Family
ID=41090241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512115A Withdrawn JP2011521660A (ja) | 2008-06-04 | 2009-06-03 | エリスロポイエチンを発酵により製造する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110189732A1 (enExample) |
| EP (1) | EP2283147A1 (enExample) |
| JP (1) | JP2011521660A (enExample) |
| CN (1) | CN102057053A (enExample) |
| BR (1) | BRPI0913622A2 (enExample) |
| CA (1) | CA2727045A1 (enExample) |
| DE (1) | DE102008002210A1 (enExample) |
| IL (1) | IL209655A0 (enExample) |
| WO (1) | WO2009147175A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691145B2 (en) | 2009-11-16 | 2014-04-08 | Flodesign Sonics, Inc. | Ultrasound and acoustophoresis for water purification |
| US9421553B2 (en) | 2010-08-23 | 2016-08-23 | Flodesign Sonics, Inc. | High-volume fast separation of multi-phase components in fluid suspensions |
| US9752114B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc | Bioreactor using acoustic standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10370635B2 (en) | 2012-03-15 | 2019-08-06 | Flodesign Sonics, Inc. | Acoustic separation of T cells |
| US9783775B2 (en) | 2012-03-15 | 2017-10-10 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US9567559B2 (en) | 2012-03-15 | 2017-02-14 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9796956B2 (en) | 2013-11-06 | 2017-10-24 | Flodesign Sonics, Inc. | Multi-stage acoustophoresis device |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US10953436B2 (en) | 2012-03-15 | 2021-03-23 | Flodesign Sonics, Inc. | Acoustophoretic device with piezoelectric transducer array |
| US9272234B2 (en) | 2012-03-15 | 2016-03-01 | Flodesign Sonics, Inc. | Separation of multi-component fluid through ultrasonic acoustophoresis |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9688958B2 (en) | 2012-03-15 | 2017-06-27 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9422328B2 (en) | 2012-03-15 | 2016-08-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US11324873B2 (en) | 2012-04-20 | 2022-05-10 | Flodesign Sonics, Inc. | Acoustic blood separation processes and devices |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| EP3019606B1 (en) * | 2013-07-12 | 2018-09-05 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| CN103820514B (zh) * | 2014-03-10 | 2017-10-31 | 深圳赛保尔生物药业有限公司 | 一种高效生产促红细胞生成素的方法 |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| US10610804B2 (en) | 2014-10-24 | 2020-04-07 | Life Technologies Corporation | Acoustically settled liquid-liquid sample purification system |
| US10106770B2 (en) | 2015-03-24 | 2018-10-23 | Flodesign Sonics, Inc. | Methods and apparatus for particle aggregation using acoustic standing waves |
| US9670477B2 (en) | 2015-04-29 | 2017-06-06 | Flodesign Sonics, Inc. | Acoustophoretic device for angled wave particle deflection |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| EP3297740A1 (en) | 2015-05-20 | 2018-03-28 | Flodesign Sonics Inc. | Acoustic manipulation of particles in standing wave fields |
| US10161926B2 (en) | 2015-06-11 | 2018-12-25 | Flodesign Sonics, Inc. | Acoustic methods for separation of cells and pathogens |
| US9663756B1 (en) | 2016-02-25 | 2017-05-30 | Flodesign Sonics, Inc. | Acoustic separation of cellular supporting materials from cultured cells |
| CN112044720B (zh) | 2015-07-09 | 2023-07-04 | 弗洛设计声能学公司 | 非平面和非对称压电晶体及反射器 |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US10710006B2 (en) | 2016-04-25 | 2020-07-14 | Flodesign Sonics, Inc. | Piezoelectric transducer for generation of an acoustic standing wave |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CN114891635A (zh) | 2016-05-03 | 2022-08-12 | 弗洛设计声能学公司 | 利用声泳的治疗细胞洗涤、浓缩和分离 |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
| EP0318487B1 (en) | 1986-08-04 | 1993-10-13 | The University Of New South Wales | Serum free tissue culture medium containing polymeric cell-protective agent |
| US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| IT1256566B (it) | 1990-11-30 | 1995-12-11 | Ajinomoto Kk | Procedimento e apparecchiatura per controllare la concentrazione della sorgente di carbonio in una coltura aerobica di un microorganismo |
| US5626767A (en) | 1993-07-02 | 1997-05-06 | Sonosep Biotech Inc. | Acoustic filter for separating and recycling suspended particles |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| IL118201A (en) * | 1995-05-11 | 2004-12-15 | Roche Diagnostics Gmbh | Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof |
| DE69722391T2 (de) | 1996-03-13 | 2004-04-22 | Delta Biotechnology Ltd. | Gärungs-steuerungssysteme |
| WO1999028455A1 (de) * | 1997-12-03 | 1999-06-10 | Roche Diagnostics Gmbh | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
| BR9917606A (pt) * | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
| US20020099183A1 (en) | 2000-08-23 | 2002-07-25 | Pluschkell Stefanie Beate | Process for the preparation of neutrophil inhibitory factor |
| DE10255508A1 (de) * | 2002-11-27 | 2004-06-17 | Forschungszentrum Jülich GmbH | Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen |
| DE102004027816A1 (de) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von Erythropoietin |
| ES2434494T3 (es) * | 2005-12-08 | 2013-12-16 | Amgen, Inc. | Células huésped mejoradas y métodos de cultivo |
| US10982250B2 (en) * | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
| DE102007042600A1 (de) * | 2007-09-07 | 2009-03-12 | Evonik Degussa Gmbh | Verfahren zur Herstellung von enantiomerenangereichten Aminen |
-
2008
- 2008-06-04 DE DE102008002210A patent/DE102008002210A1/de not_active Withdrawn
-
2009
- 2009-06-03 JP JP2011512115A patent/JP2011521660A/ja not_active Withdrawn
- 2009-06-03 BR BRPI0913622-3A patent/BRPI0913622A2/pt not_active IP Right Cessation
- 2009-06-03 US US12/996,070 patent/US20110189732A1/en not_active Abandoned
- 2009-06-03 WO PCT/EP2009/056820 patent/WO2009147175A1/de not_active Ceased
- 2009-06-03 EP EP09757556A patent/EP2283147A1/de not_active Withdrawn
- 2009-06-03 CA CA2727045A patent/CA2727045A1/en not_active Abandoned
- 2009-06-03 CN CN2009801207656A patent/CN102057053A/zh active Pending
-
2010
- 2010-11-30 IL IL209655A patent/IL209655A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009147175A1 (de) | 2009-12-10 |
| CA2727045A1 (en) | 2009-12-10 |
| BRPI0913622A2 (pt) | 2015-08-25 |
| EP2283147A1 (de) | 2011-02-16 |
| DE102008002210A1 (de) | 2009-12-10 |
| US20110189732A1 (en) | 2011-08-04 |
| IL209655A0 (en) | 2011-02-28 |
| CN102057053A (zh) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110189732A1 (en) | Process for the Fermentative Production of Erythropoietin | |
| US20230313125A1 (en) | Perfusion medium | |
| CN107254499B (zh) | 改进的细胞培养方法 | |
| JP6393267B2 (ja) | かん流細胞培養システムを最適化するための方法およびシステム | |
| TWI625390B (zh) | 用於增加重組蛋白質之甘露糖含量之方法 | |
| JP2017500017A (ja) | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 | |
| KR101286895B1 (ko) | 골 형태발생 단백질의 개선된 생산 방법 | |
| CN110462054B (zh) | 灌注培养基 | |
| US20250115890A1 (en) | Improved media for the expression of recombinant vitamin k-dependent proteins | |
| CN114729306B (zh) | 浓缩灌注培养基 | |
| US11396540B1 (en) | Methods for making recombinant proteins | |
| Ljunggren et al. | Specific growth rate as a parameter for tracing growth-limiting substances in animal cell cultures | |
| KR20160113710A (ko) | 관류 배지 | |
| RU2836899C1 (ru) | Композиция питательных сред для культивирования клеток СНО, экспрессирующих моноклональное антитело пембролизумаб | |
| CN121975721A (zh) | 一种用于cho细胞培养的添加剂组合物及其应用 | |
| KR20240172522A (ko) | 지속형 호르몬 수용체 길항제의 생산 방법 | |
| HK1157401A (en) | Methods for enhanced production of bone morphogenetic proteins | |
| WO2017102794A1 (en) | Method for increasing the heterogeneity of o-glycosylation of recombinant factor vii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120515 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120515 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130613 |